These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9517965)

  • 1. Selection of fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus with ciprofloxacin and trovafloxacin.
    Evans ME; Titlow WB
    Antimicrob Agents Chemother; 1998 Mar; 42(3):727. PubMed ID: 9517965
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus.
    Kim YS; Liu Q; Chow LL; Chambers HF; Täuber MG
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3325-7. PubMed ID: 9835540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin.
    Bonilla HF; Zarins LT; Bradley SF; Kauffman CA
    Diagn Microbiol Infect Dis; 1996 Sep; 26(1):17-21. PubMed ID: 8950524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus.
    Fitzgibbon JE; John JF; Delucia JL; Dubin DT
    Antimicrob Agents Chemother; 1998 Aug; 42(8):2122-4. PubMed ID: 9687420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro selection of quinolone-resistant staphylococcal mutants by a single exposure to ciprofloxacin or trovafloxacin (CP-99,219) -letter-.
    Barry AL; Brown SD; Fuchs PC
    J Antimicrob Chemother; 1996 Aug; 38(2):324-7. PubMed ID: 8877554
    [No Abstract]   [Full Text] [Related]  

  • 6. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model.
    Firsov AA; Vasilov RG; Vostrov SN; Kononenko OV; Lubenko IY; Zinner SH
    J Antimicrob Chemother; 1999 Apr; 43(4):483-90. PubMed ID: 10350376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacin.
    Dubin DT; Fitzgibbon JE; Nahvi MD; John JF
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1631-7. PubMed ID: 10390214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: comparative study with seven other fluoroquinolones.
    Nishijima S; Nakagawa M; Tsuboi N; Akamatsu H; Horio T; Fujita M; Kawabata S
    J Int Med Res; 1996; 24(1):12-6. PubMed ID: 8674789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.
    Jones ME; Visser MR; Klootwijk M; Heisig P; Verhoef J; Schmitz FJ
    Antimicrob Agents Chemother; 1999 Feb; 43(2):421-3. PubMed ID: 9925551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility of recent gram-positive isolates to ciprofloxacin, levofloxacin, and trovafloxacin.
    Isenberg HD; Alperstein P; France K
    Diagn Microbiol Infect Dis; 1998 Oct; 32(2):115-8. PubMed ID: 9823535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antistaphylococcal and antistreptococcal killing kinetics of ciprofloxacin, ofloxacin, sparfloxacin, and trovafloxacin.
    Prenna M; Montanari MP; Mingoia M; Biavasco F; Ripa S; Varaldo PE
    Eur J Clin Microbiol Infect Dis; 1998 Nov; 17(11):816-9. PubMed ID: 9923533
    [No Abstract]   [Full Text] [Related]  

  • 14. [In vitro activity of trovafloxacin in 238 respiratory pathogens].
    Alarcón T; Domingo D; Prieto N; Sánchez S; López-Brea M
    Rev Esp Quimioter; 1998 Mar; 11(1):47-51. PubMed ID: 9795289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci.
    Coque TM; Singh KV; Murray BE
    J Antimicrob Chemother; 1996 May; 37(5):1011-6. PubMed ID: 8737152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro development of resistance to a novel fluoroquinolone, DW286, in methicillin-resistant Staphylococcus aureus clinical isolates.
    Kim MJ; Yun HJ; Kang JW; Kim S; Kwak JH; Choi EC
    J Antimicrob Chemother; 2003 Apr; 51(4):1011-6. PubMed ID: 12654771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.
    Cohen MA; Huband MD; Gage JW; Yoder SL; Roland GE; Gracheck SJ
    J Antimicrob Chemother; 1997 Aug; 40(2):205-11. PubMed ID: 9301985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model.
    Firsov AA; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
    Antimicrob Agents Chemother; 1999 Mar; 43(3):498-502. PubMed ID: 10049257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoroquinolone resistance among methicillin-resistant staphylococci after usage of fluoroquinolones other than ciprofloxacin in Taiwan.
    Chang SC; Hsieh WC; Luh KT
    Diagn Microbiol Infect Dis; 1994 Jul; 19(3):143-7. PubMed ID: 7820993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin.
    Harrington GD; Zarins LT; Ramsey MA; Bradley SF; Kauffman CA
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):27-31. PubMed ID: 7789094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.